
Mark Zimmerman, MD
Former Professor of Psychiatry and Human Behavior
Brown University

Treating Anxiety in Patients with Depression and Bipolar Disorder
Thursday, February 11, 2027
2:30 PM - 3:30 PM
Mark Zimmerman, MD, is a former professor of psychiatry and human behavior at Brown University in Providence, Rhode Island. He is currently the Chief of Psychiatry and Behavioral Health at South County Psychiatry in Cranston, Rhode Island, where he has adopted the academic medical center approach into a private practice setting. Dr. Zimmerman received his undergraduate degree from Columbia University, and his medical degree from Chicago Medical School.
He completed his postgraduate training at the Medical College of Pennsylvania, and he held an academic appointment as assistant professor at the same time he was a resident in psychiatry. Dr Zimmerman has been an active researcher and is a widely published author with more than 500 articles in peer reviewed journals. For the past 30 years he has been the principal investigator of the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project. The goal of the MIDAS project has been to integrate research methodology into routine clinical practice in order to improve clinical practice. He is on the editorial board of 10 journals. Dr Zimmerman has developed several instruments for clinical and research use and recently validated interviews that he developed for the DSM5-TR anxious distress and mixed features specifiers. Most recently he developed and validated a self-report scale to identify difficult to treat depression. He has won numerous awards for his research, and he served as the personality disorders section editor for the revision of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. He is the author of the recently revised Interview Guide to Diagnose DSM-5 Psychiatric Disorders and the Mental Status Examination, a leading textbook for psychiatric diagnosis and assessment. Dr. Zimmerman is the editor of the psychiatry section of the Merck Manual.
Lecture Summary:
This presentation will examine the prevalence and clinical impact of anxiety in patients with depression and bipolar disorder, including how frequently anxiety symptoms and disorders may go unrecognized. The session will review practical approaches to improving identification, including use of the anxious distress specifier and screening measures for anxiety. It will also address how co-occurring anxiety can affect treatment response, tolerability, and overall outcomes, while reviewing treatment strategies for patients experiencing both mood disorders and anxiety.
Goals and Learning Objectives:
-
Become familiar with the frequency of anxiety disorders in patients with depression and bipolar disorder; the psychosocial morbidity associated with anxiety disorders in these patients; how often anxiety disorders are underrecognized; and methods to improve recognition.
-
Describe the treatment implications of anxiety disorders in patients with depression and bipolar disorder regarding overall response to treatment, occurrence of side effects, and differential treatment response.
-
Review treatments that are effective in patients with depression and bipolar disorder and co-occuring anxiety
Disclosures:
Advisory Board : Johnson & Johnson, Oryzon Genomics
Speakers' Bureau or Honoraria : Johnson & Johnson
Ownership Interest (privately held) : Psych Products Press
.png)